All

WHO Updates Terminology for Airborne Pathogens

The report introduces the term "infectious respiratory particles" and advocates for moving away from the dichotomy of the previously used terms "aerosols" and "droplets."

All

10 States Where Nighttime Coughs Are Keeping People Awake

Sleep tracking app Sleep Cycle analyzed over 2 million hours of sleep to understand how coughing may be affecting users' sleep health.

All

Beyfortus Approved in China to Prevent RSV Infants

AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season.

CDC Recommends Beyfortus RSV Vaccine for Infants

by RT Staff | Aug 3, 2023 | Neonatal, Other Infections, Pediatric Care, US Pharmaceuticals | 0

CDC is recommending the novel RSV vaccine Beyfortus (nirsevimab, Sanofi and AstraZeneca) starting this fall to help protect all infants under 8 months and some older babies at increased risk of severe illness caused by respiratory syncytial virus.

COVID-19, Flu, and RSV Co-Infection Rates Last Season Determined

by RT Staff | Aug 1, 2023 | Influenza, Other Infections | 0

Scientists are providing one of the first snapshots of the interplay among these three common but potentially deadly viruses.

FDA Approves RSV Shot for Infants

by RT Staff | Jul 18, 2023 | FDA Approvals, Other Infections, Pediatrics, US Pharmaceuticals | 0

Beyfortus is the first preventive option approved to protect a broad infant population, including those born healthy at term, preterm, or with specific health conditions that make them vulnerable to severe RSV disease.

RSV Prophylactic Delays Exacerbated Pediatric Hospitalizations During Unusual RSV Surges

by RT Staff | Jul 17, 2023 | Other Infections, Pediatric Care, US Pharmaceuticals | 0

In 2021, RSV season began in May, leaving kids without a prophylactic until September, due to lack of drug availability and challenges with insurance authorization for off-season administration.

Moderna Makes Regulatory Submissions for RSV Vaccine Candidate

by RT Staff | Jul 13, 2023 | Industry & Regulatory News, Other Infections, Pharmaceuticals | 0

Moderna has submitted marketing authorization applications for its investigational RSV vaccine with the European Medicines Agency, Swissmedic, and the Therapeutic Goods Administration in Australia and initiated a rolling submission of a Biologics License Application to the FDA.

CDC Recommends GSK, Pfizer RSV Vaccines For Older Adults

by RT Staff | Jun 29, 2023 | Industry & Regulatory News, Other Infections, US Pharmaceuticals | 0

The CDC is recommending use of two new RSV vaccines from GSK and Pfizer for people ages 60 years and older.

FDA Approves Pfizer’s RSV Vaccine

by RT Staff | Jun 2, 2023 | FDA Approvals, Other Infections, US Pharmaceuticals | 0

The FDA approved Abrysvo for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years and older.

FDA Clears Hologic’s Test to Detect SARS-CoV-2, Influenza A/B, and RSV

by RT Staff | May 19, 2023 | Diagnostics, Other Infections, Testing | 0

According to Hologic, the test will be a critical tool this upcoming season to help clinicians determine which respiratory virus or coinfection patients have to better inform the best course of treatment.

FDA Approves First RSV Vaccine

by RT Staff | May 3, 2023 | FDA Approvals, Other Infections, US Pharmaceuticals | 0

In clinical trials, the vaccine significantly reduced the risk of developing RSV-associated lower respiratory tract disease by 82.6% and reduced the risk of developing severe RSV-associated lower respiratory tract disease by 94.1% in adults age 60 and older.

Tag: RSV respiratory syncytial virus

All

All

All